
What happens to pharmacy benefit design and community pharmacies as PBM markets become more concentrated? --- Researchers from the National Pharmaceutical Council examined PBM market concentration and formulary structures across states from 2016 to 2025. Their sample included 267 million enrollees in 2025. They found: 📈 Average state-level PBM market concentration, measured by the Herfindahl-Hirschman Index (HHI), increased from 1,235 to 3,002. ↳ For context, under current DOJ/FTC guidelines, an HHI above 1,800 signals high concentration and a risk of market power. 💊 The share of enrollees in formularies with more than three tiers increased from 29.8% to 40.3%. ↳ Formularies with more than 3 tiers may include a specialty tier, which typically imposes higher cost sharing on patients. 📊 Across the state-years studied, 46.3% of the population in highly concentrated PBM markets lived in counties with net community pharmacy closures, compared with 18.2% in unconcentrated markets. --- The study shows an association. It does not establish that PBM concentration caused the increase in tiers or pharmacy closures. Many factors could contribute, including changes in the mix of drugs available, growth in specialty therapies, plan sponsor benefit design choices, and the use of tiers to encourage preferred products and negotiate manufacturer concessions. The number of tiers also doesn’t tell us everything about what patients pay. A fourth tier may carry higher cost sharing, but copayments, coinsurance, deductibles, and the drugs a patient needs all matter too. In our recent Drug Channels analysis of employer benefits, we found that HSA-qualified plans often had fewer tiers than other plans--but workers in those tiered benefits were more likely to face coinsurance for higher-tier drugs. Pharmacy closures have been very common the last few years, but the impact of a pharmacy closure depends on where it happens. In another Drug Channels blog, we described the pharmacy shakeout as K-shaped: patients in a dense market may have several nearby alternatives, while a rural community can lose its only pharmacy. --- Ultimately the NPC study is using data to show trends that can impact patient access to drugs. These results are more evidence on the potential links between PBM concentration and patient access. Policymakers may be interested 👀
















